Local websites
Businesses
Other websites
General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

More information

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

More information

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

More information

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Innovation at Novartis

Please turn on your Javascript to use this Video-Player

Bringing new and better medicines to patients as quickly as possible. »

Research and development

Our R&D strategy is driven by innovative science and guided by patient needs. »

Focused diversification

Novartis drives innovation across a broad range of divisions. »

Getting drugs to patients faster

To ensure patients can benefit from new, innovative drugs as quickly as possible, Novartis works with regulators, health professionals and payors around the world to tailor our offering to meet local patient
needs. »

Focus on patient outcomes

Novartis invests in the development of new technologies that improve patient adherence and help predict individual response to treatment. »

Innovation for the developing world

Novartis is committed to researching vaccines and medicines for diseases of the developing world. »

Responsibly tackling the challenging issues

Novartis is committed to upholding high standards of ethics across our business including our R&D efforts. »

Top links
Top downloads
Annual report 2012

Annual report 2012 >